BACKGROUND: Newborn screening (NBS) for CF has become widespread, although there are multiple strategies. Little is known about outcomes such as age of diagnosis after different NBS methods. METHODS: We used the U.S. Cystic Fibrosis Foundation Patient Registry to identify infants with CF born between 2001 and 2008 in states that utilized NBS. We compared ages at diagnosis, genotyping, sweat test, and first visit to a CF Centre between states that used serial immunoreactive trypsinogen (IRT/IRT) levels and states that used IRT and DNA analysis (IRT/DNA). RESULTS: We identified 1288 infants with CF. Compared to infants born in IRT/IRT states, infants born in IRT/DNA states were younger at the time of diagnosis (median 2.3 weeks versus 4.0 weeks in IRT/IRT states, p<0.001), genotyping (0.7 weeks versus 5.3 weeks, p<0.001), and initial CF Centre visit (5.9 weeks versus 7.7 weeks, p=0.008). CONCLUSIONS: Although there is room to improve outcomes with both strategies, infants born in IRT/DNA states have treatment initiated at a younger age than infants born in IRT/IRT states. Copyright Â
BACKGROUND: Newborn screening (NBS) for CF has become widespread, although there are multiple strategies. Little is known about outcomes such as age of diagnosis after different NBS methods. METHODS: We used the U.S. Cystic Fibrosis Foundation Patient Registry to identify infants with CF born between 2001 and 2008 in states that utilized NBS. We compared ages at diagnosis, genotyping, sweat test, and first visit to a CF Centre between states that used serial immunoreactive trypsinogen (IRT/IRT) levels and states that used IRT and DNA analysis (IRT/DNA). RESULTS: We identified 1288 infants with CF. Compared to infants born in IRT/IRT states, infants born in IRT/DNA states were younger at the time of diagnosis (median 2.3 weeks versus 4.0 weeks in IRT/IRT states, p<0.001), genotyping (0.7 weeks versus 5.3 weeks, p<0.001), and initial CF Centre visit (5.9 weeks versus 7.7 weeks, p=0.008). CONCLUSIONS: Although there is room to improve outcomes with both strategies, infants born in IRT/DNA states have treatment initiated at a younger age than infants born in IRT/IRT states. Copyright Â
Authors: Anne Marie Comeau; Frank J Accurso; Terry B White; Preston W Campbell; Gary Hoffman; Richard B Parad; Benjamin S Wilfond; Margaret Rosenfeld; Marci K Sontag; John Massie; Philip M Farrell; Brian P O'Sullivan Journal: Pediatrics Date: 2007-02 Impact factor: 7.124
Authors: Kevin W Southern; Anne Munck; Rodney Pollitt; Georges Travert; Luisa Zanolla; Jeannette Dankert-Roelse; Carlo Castellani Journal: J Cyst Fibros Date: 2006-07-25 Impact factor: 5.482
Authors: Michael J Rock; Gary Hoffman; Ronald H Laessig; Greg J Kopish; Thomas J Litsheim; Philip M Farrell Journal: J Pediatr Date: 2005-09 Impact factor: 4.406
Authors: H C Lai; M R Kosorok; S A Sondel; S T Chen; S C FitzSimmons; C G Green; G Shen; S Walker; P M Farrell Journal: J Pediatr Date: 1998-03 Impact factor: 4.406